How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Business Services · Forecast 2027–2033
Epithelial Ovarian Cancer Market
- By Histological Subtype: Serous carcinoma, Endometrioid carcinoma, Clear cell carcinoma, Mucinous carcinoma, Transitional cell carcinoma
- By Stage of Cancer: Stage I, Stage II, Stage III, Stage IV
- By Treatment Modality: Surgery, Chemotherapy, Targeted therapy, Immunotherapy, Radiation therapy
- By Drug Class: Platinum-based agents, PARP inhibitors, Anti-angiogenic agents, Taxanes, Topoisomerase inhibitors
- By Patient Population: Recurrent ovarian cancer, Platinum-sensitive ovarian cancer, Platinum-resistant ovarian cancer, Newly diagnosed ovarian cancer
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Serous carcinoma leads By Histological Subtype at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 300 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.182 →
- 12 Company Profiles 15 players: SWOT & benchmarking p.190 →
Full report · locked preview
Everything inside the Epithelial Ovarian Cancer Market report
A complete, evidence-based study - 12 chapters and 126 sections covering market size, segmentation across 5 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Histological Subtype 5
Stage of Cancer 4
Treatment Modality 5
Drug Class 5
Patient Population 4
Companies profiled
Roche
AstraZeneca
GlaxoSmithKline (GSK)
Pfizer
Clovis Oncology
Tesaro (a GSK company)
Novartis
Bristol-Myers Squibb
Merck & Co.
Eli Lilly and Company
AbbVie
BeiGene
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Roche
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →AstraZeneca
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →GlaxoSmithKline (GSK)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Pfizer
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Clovis Oncology
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Tesaro (a GSK company)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Novartis
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Bristol-Myers Squibb
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Merck & Co.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Eli Lilly and Company
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →AbbVie
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →BeiGene
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Zai Lab
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Seattle Genetics (Seagen)
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Amgen
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$7,565M by 2033 · 9.3% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Serous carcinoma44.0
- Endometrioid carcinoma14.7
- Clear cell carcinoma10.8
- Mucinous carcinoma14.6
- Transitional cell carcinoma15.8
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,226M → $2,249M · 7.9%
Europe$854.4M → $1,563M · 7.8%
Asia Pacific$780.1M → $1,575M · 9.2%
Latin America$482.9M → $1,068M · 10.4%
Middle East and Africa$371.5M → $738.6M · 9.0%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →9.242026
9.252027
9.272028
9.282029
9.292030
9.312031
9.322032
9.342033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Roche15.8
- AstraZeneca15.3
- GlaxoSmithKline (GSK)9.5
- Pfizer10.0
- Clovis Oncology11.1
- Tesaro (a GSK company)10.3
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Histological Subtype22.4%
Stage of Cancer27.3%
Treatment Modality11.3%
Drug Class17.9%
Patient Population21.1%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America31.3
- Europe21.7
- Asia Pacific21.9
- Latin America14.8
- Middle East and Africa10.3
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Roche | 83 | 84 | 92 | 93 | 75 | 75 | 84 |
| AstraZeneca | 89 | 76 | 78 | 71 | 68 | 72 | 76 |
| GlaxoSmithKline (GSK) | 64 | 64 | 64 | 77 | 66 | 85 | 70 |
| Pfizer | 75 | 66 | 79 | 66 | 66 | 66 | 70 |
| Clovis Oncology | 54 | 71 | 63 | 75 | 62 | 58 | 64 |
| Tesaro (a GSK company) | 68 | 67 | 64 | 58 | 53 | 53 | 61 |
| Novartis | 65 | 56 | 43 | 60 | 44 | 49 | 53 |
| Bristol-Myers Squibb | 49 | 52 | 53 | 49 | 45 | 44 | 49 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Roche
- AstraZeneca
- GlaxoSmithKline (GSK)
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Roche | ✓ | ◐ | ✓ | ✓ | ✓ | ◐ |
| AstraZeneca | ◐ | − | ◐ | ✓ | ◐ | ◐ |
| GlaxoSmithKline (GSK) | ◐ | ◐ | ◐ | ✓ | ◐ | ✓ |
| Pfizer | ✓ | ◐ | ◐ | ◐ | ◐ | ✓ |
| Clovis Oncology | ◐ | ◐ | − | ◐ | − | − |
| Tesaro (a GSK company) | − | − | ◐ | − | ◐ | ◐ |
| Novartis | ◐ | ◐ | − | ◐ | ◐ | ◐ |
| Bristol-Myers Squibb | − | − | − | − | − | ◐ |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Roche84
2AstraZeneca76
3GlaxoSmithKline (GSK)70
4Pfizer70
5Clovis Oncology64
6Tesaro (a GSK company)61
7Novartis53
8Bristol-Myers Squibb49
Competitive tiers
§8.4 · p.172 →Leader1
Set the pace on share, breadth and innovation.
Roche
Challenger3
Strong scale, closing on the leaders.
AstraZenecaGlaxoSmithKline (GSK)Pfizer
Contender2
Focused players with pockets of strength.
Clovis OncologyTesaro (a GSK company)
Niche2
Specialists in a single segment or region.
NovartisBristol-Myers Squibb
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Histological Subtype in North America, then scale across Epithelial Ovarian Cancer Market — a $116M beachhead inside a $1.87B market.
Beachhead (SOM)$116Mobtainable near-term
Serviceable (SAM)$708Mreachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale4 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion92 fit
Serous carcinoma
Best fit — highest urgency & budget in Histological Subtype.
Economic buyer78 fit
Endometrioid carcinoma
Strong fit — clear ROI and a fast path to value.
End user67 fit
Clear cell carcinoma
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Histological Subtype in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Stage of Cancer & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Treatment Modality
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales42%
Partner / channel31%
Digital / self-serve20%
Marketplaces7%
Positioning & messaging
§GTM 2 · p.194 →For Histological Subtype leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Epithelial Ovarian Cancer Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified44%
Sales qualified20%
Evaluation13%
Closed-won7%
$21.9KCAC
$115KLTV
5.2:1LTV : CAC
< 4 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Epithelial Ovarian Cancer Market is a high-growth opportunity — $1.17B by 2033, compounding at 10.2%.
TAM · 2025$539Mtoday
TAM · 2033$1.17Bforecast
CAGR10.2%2027–2033
Cumulative$7.37Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$1.17BTotal addressable market
SAM$475MServiceable available market
SOM$104MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →10.2% CAGR
Demand compounds through 2033, outpacing GDP across Histological Subtype.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Histological Subtype moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$1.17BLarge & growingTAM by 2033 at 10.2% CAGR
$475MServiceable nowreachable with today’s model
$104MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$912MBear6.6% CAGR
$1.17BBase10.2% CAGR
$1.50BBull13.4% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Stage of Cancer optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Epithelial Ovarian Cancer Market — a $6.53B market by 2033. Plan: grow share from 6.0% to 11.5%.
Market size · 2033$6.53Btotal addressable
Market CAGR3.8%2027–2033
Target share11.5%from 6.0% today
Revenue ambition$751Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 6.0% | 11.5% | On track |
| Revenue | $398M | $751M | Ahead |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Behind |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | On track |
| Gross margin | 35.5% | 44.2% | On track |
| Customer retention | 91.8% | 93.4% | At risk |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Histological Subtype
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Stage of Cancer capability
A defensible second engine — invest in Stage of Cancer to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Histological Subtype share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Stage of Cancer
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $91M capacity & capability investment
- Greenlight bolt-on M&A in Stage of Cancer
- Authorise North America expansion plan
- Fund R&D program for Histological Subtype leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossBehind
- Input-cost & supply riskBehind
- Regulatory / policy changeOn track
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Epithelial Ovarian Cancer Market conversation — a $6.81B market you can size, segment and defend in minutes.
Market size · 2033$6.81Btotal opportunity
Growth3.6%CAGR to 2033
Addressable buyers1,731+accounts in scope
Typical ROI4.9×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Histological Subtype
Goal Grow share in Histological Subtype
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →4.9×return on cost, year one
< 3 mopayback period
$93K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
RocheAstraZenecaGlaxoSmithKline (GSK)PfizerClovis OncologyTesaro (a GSK company)NovartisBristol-Myers Squibb+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Epithelial Ovarian Cancer Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Epithelial Ovarian Cancer Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Business Services · scroll →EPM Rubber Market
Market size, share, segmentation and regional forecast.
$884M market · 2025 base year
View reportEPM Software Market
Market size, share, segmentation and regional forecast.
$6.0B market · 2025 base year
View reportEpoetin Alfa Market
Market size, share, segmentation and regional forecast.
$5.7B market · 2025 base year
View reportEpoetin Beta Market
Market size, share, segmentation and regional forecast.
$865M market · 2025 base year
View reporte-poly-L-lysine (e-PL) Market
Market size, share, segmentation and regional forecast.
$3.6B market · 2025 base year
View reportePOS Systems in Hospitality Market
Market size, share, segmentation and regional forecast.
$3.8B market · 2025 base year
View reportEpoxidized Soybean Oil (ESBO) Market
Market size, share, segmentation and regional forecast.
$1.0B market · 2025 base year
View reportEpoxidized Soybean Oil (ESO) Market
Market size, share, segmentation and regional forecast.
$1.4B market · 2025 base year
View reportEpoxidized Styrene-Isoprene-Styrene Market
Market size, share, segmentation and regional forecast.
$3.6B market · 2025 base year
View reportEpoxy Acrylate Coating Market
Market size, share, segmentation and regional forecast.
$2.2B market · 2025 base year
View reportEpoxy Adhesives for Encapsulation Market
Market size, share, segmentation and regional forecast.
$837M market · 2025 base year
View reportEpoxy Aluminum Coating Market
Market size, share, segmentation and regional forecast.
$5.0B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.